Last reviewed · How we verify
Brimonidine purite 0.15%
Brimonidine is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Brimonidine is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Brimonidine purite 0.15% |
|---|---|
| Also known as | Alphagan P 0.15% |
| Sponsor | Northwestern Ophthalmic Institute S.C. |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Brimonidine selectively binds to alpha-2 adrenergic receptors on the ciliary body and trabecular meshwork of the eye. This activation reduces the production of aqueous humor while simultaneously enhancing its drainage through the uveoscleral pathway, thereby lowering intraocular pressure. The purite formulation is a preserved formulation designed for topical ophthalmic use.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular hyperemia
- Ocular allergic reactions
- Dry mouth
- Fatigue
- Headache
- Blurred vision
Key clinical trials
- The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients (PHASE4)
- Brimonidine for Intraoperative Hemostasis (PHASE4)
- Superior vs Temporal Laser Peripheral Iridotomy in Primary Angle Closure Suspects (PACS) (NA)
- Brimonidine Tartrate for Pterygium Surgery (NA)
- Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial (PHASE4)
- Brimonidine for Subconjunctival Hemorrhage From Femtosecond Laser Assisted Cataract Surgery (NA)
- Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD) (PHASE1, PHASE2)
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brimonidine purite 0.15% CI brief — competitive landscape report
- Brimonidine purite 0.15% updates RSS · CI watch RSS
- Northwestern Ophthalmic Institute S.C. portfolio CI